Compartilhar
Informação da revista
Vol. 98. Núm. 4.
Páginas 520-523 (1 julho 2023)
Compartilhar
Compartilhar
Baixar PDF
Mais opções do artigo
Visitas
3543
Vol. 98. Núm. 4.
Páginas 520-523 (1 julho 2023)
Letter - Research
Acesso de texto completo
Scanning electron microscopy of ibrutinib-induced hair shaft changes
Visitas
3543
Hiram Larangeira de Almeida Jr.a,b,
Autor para correspondência
hiramalmeidajr@hotmail.com

Corresponding author.
, Debora Sarzi Sartorib, Douglas Malkouna, Carlos Eduardo Pouey Cunhaa
a Department of Dermatology, Universidade Federal de Pelotas, Pelotas, RS, Brazil
b Graduate Program in Health and Behavior, Universidade Católica de Pelotas, Pelotas, RS, Brazil
Este item recebeu
Informação do artigo
Texto Completo
Bibliografia
Baixar PDF
Estatísticas
Figuras (4)
Mostrar maisMostrar menos
Texto Completo
Dear Editor,

Bruton's tyrosine kinase (BTK) is essential for the development and maturation of B-lymphocytes. These cells do not mature in individuals with mutations in this enzyme, and they have X-linked agammaglobulinemia, the most common type of congenital agammaglobulinemia.1

BTK is also expressed in tumor cells, and its inhibition is gaining increasing importance in the treatment of B-lineage neoplasms.2 BTK participates in the activation of these cells, being important for the survival of malignant B cells and, therefore, its inhibition decreases their proliferation and survival.

Ibrutinib is a potent irreversible BTK inhibitor and was the first inhibitor of this enzyme approved by the FDA for the treatment of the following diseases in adults: 1) Chronic graft-versus-host disease, after the failure of one or more systemic therapy lines; 2) Chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SCLL); 3) CLL/SCLL in adults with 17p deletion; 4) Mantle-cell lymphoma in adults who have received at least one prior therapy; 5) Relapsed/refractory marginal zone lymphoma, in adults who require systemic therapy and have received at least one prior anti-CD20-based therapy; and 6) In Waldenström's macroglobulinemia.3

The described side effects are fatigue, diarrhea, peripheral edema, cardiac arrhythmia (atrial fibrillation), bleeding, and infections (respiratory tract).4–6

Ibrutinib can have cutaneous adverse effects, with a peak incidence in the first year of treatment. The most common manifestations are skin rash, petechiae and ecchymosis. Also, urticaria, herpes simplex and herpes zoster reactivation, panniculitis, and Stevens-Johnson syndrome may occur.6,7

Despite the specificity for BTK, some skin effects are similar to those produced by EGF (epidermal growth factor) inhibitors,8 such as the described acneiform rash, changes in hair/eyelashes,9 and longitudinal grooves on nails.

A 72-year-old patient who had received ibrutinib for six months to treat mantle lymphoma unresponsive to conventional therapy was assessed. The patient reported a slight alteration in his hair, with a change in its curling (Fig. 1). Some hair shafts were cut and examined in natura with scanning electron microscopy. At medium magnification, discreet longitudinal channels were observed in the hair shafts (Fig. 2A and B), which are not seen in normal hair (Fig. 2C). At high magnification, these channels were very evident (Figs. 3 and 4).

Figure 1.

Modification in hair curl pattern.

(0.17MB).
Figure 2.

Scanning electron microscopy. (A. and B) Medium magnification showing discreet hair shaft channels (×300 and 270). (C) normal control (×300).

(0.13MB).
Figure 3.

Scanning electron microscopy. High magnification revealing a channel in the hair shaft (×550).

(0.16MB).
Figure 4.

Scanning electron microscopy. High magnification showing a channel in the hair shaft (×650).

(0.16MB).

The authors did not find any reports in the literature of an examination of hairs shafts with scanning electron microscopy showing alterations caused by ibrutinib. There are some reports with EGF inhibitors, in which channels were also described in the hair shafts,9 in this case with greater clinical consequences, making the hair frizzy and the eyelashes elongated (trichomegaly) and without curvature. The channels seen in these drug-induced cases are similar to those seen in families with uncombable hair,10 and in a syndromic type of pili canaliculi associated with a central nervous system degeneration called giant axonal neuropathy.11

The findings of this patient demonstrate, on ultrastructural examination, a similarity between the alterations of EGF and BTK inhibitors.

BTK inhibition is an expanding concept in the treatment of hematologic malignancies, with 22 drugs under development, and the emergence of drugs with less systemic and cutaneous toxicity is possible in the near future.10,12

Financial support

None declared.

Authors' contributions

Hiram Larangeira de Almeida Jr: Approval of the final version of the manuscript; design and planning of the study; drafting and editing of the manuscript; collection, analysis, and interpretation of data; effective participation in research orientation; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the literature; critical review of the manuscript.

Debora Sarzi Sartori: Approval of the final version of the manuscript; design and planning of the study; drafting and editing of the manuscript; collection, analysis, and interpretation of data; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the literature; critical review of the manuscript.

Douglas Malkoun: Approval of the final version of the manuscript; design and planning of the study; drafting and editing of the manuscript; collection, analysis, and interpretation of data; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the literature; critical review of the manuscript.

Carlos Eduardo Pouey Cunha: Approval of the final version of the manuscript; design and planning of the study; drafting and editing of the manuscript; collection, analysis, and interpretation of data; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the literature; critical review of the manuscript.

Conflicts of interest

None declared.

References
[1]
M. Cardenas-Morales, V.P. Hernandez-Trujillo.
Agammaglobulinemia: from X-linked to Autosomal Forms of Disease.
Clin Rev Allergy Immunol., 63 (2022), pp. 22-35
[2]
S. Pal Singh, F. Dammeijer, R.W. Hendriks.
Role of Bruton’s tyrosine kinase in B cells and malignancies.
Mol Cancer., 17 (2018), pp. 57
[3]
update.com [Internet]. Ibrutinibe: informações sobre medicamentos. UpToDate. [cited 2022 Aug 08]. Available from: https://www.uptodate.com/contents/ibrutinib-drug-information.
[4]
S. Paydas.
Management of adverse effects/toxicity of ibrutinib.
Crit Rev Oncol Hematol., 136 (2019), pp. 56-63
[5]
M. Lasica, C.S. Tam.
Management of Ibrutinib Toxicities: a Practical Guide.
Curr Hematol Malig Rep., 15 (2020), pp. 177-186
[6]
A. Lipsky, N. Lamanna.
Managing toxicities of Bruton tyrosine kinase inhibitors.
Hematology Am Soc Hematol Educ Program., 2020 (2020), pp. 336-345
[7]
V. Sibaud, M. Beylot-Barry, C. Protin, E. Vigarios, C. Recher, L. Ysebaert.
Dermatological Toxicities of Bruton’s Tyrosine Kinase Inhibitors.
Am J Clin Dermatol., 21 (2020), pp. 799-812
[8]
S. Singer, S.Y. Tan, A.K. Dewan, M. Davids, A.S. LaCasce, S.P. Treon, et al.
Cutaneous Eruptions from Ibrutinib Resembling EGFR Inhibitor-Induced Dermatologic Adverse Events.
J Am Acad Dermatol., 20 (2019),
[9]
D.S. Sartori, A.L. Almeida, G.S.P. Oliveira, H.L. Almeida Jr.
Scanning electron microscopy of panitumumab-induced eyelash and hair alterations - Pili canaliculi.
An Bras Dermatol., 97 (2022), pp. 240-242
[10]
R.R. Cunha Filho, H.L. Almeida Jr, N.M. Rocha, L.A.S. Castro.
Uncombable hair syndrome (pili trianguli et canaliculi): clinical variation in 12 members of one family.
An Bras Dermatol., 83 (2008), pp. 53-55
[11]
H.L. Almeida Jr, G. Garcias, R.M. Silva, S.L. Batista, F. Pasetto.
Pili canaliculi as manifestation of giant axonal neuropathy.
An Bras Dermatol., 91 (2016), pp. 125-127
[12]
H.Y. Estupiñán, A. Berglöf, R. Zain, C.I.E. Smith.
Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects.
Front Cell Dev Biol., 9 (2021),

Study conducted at the Graduate Program in Health and Behavior, Universidade Católica de Pelotas, Pelotas, RS, Brazil.

Copyright © 2023. Sociedade Brasileira de Dermatologia
Baixar PDF
Idiomas
Anais Brasileiros de Dermatologia (Portuguese)
Opções de artigo
Ferramentas
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.